Enzo Biochem, Inc. (NYSE:ENZ) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.62 and traded as high as $3.63. Enzo Biochem shares last traded at $3.56, with a volume of 213,934 shares.
Separately, TheStreet upgraded shares of Enzo Biochem from a “d+” rating to a “c” rating in a research note on Thursday, March 18th.
The business’s 50 day moving average price is $3.26 and its 200-day moving average price is $2.63. The company has a current ratio of 2.09, a quick ratio of 1.85 and a debt-to-equity ratio of 0.08. The company has a market cap of $168.32 million, a price-to-earnings ratio of -8.07 and a beta of 0.89.
Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings data on Monday, March 15th. The medical research company reported $0.09 earnings per share for the quarter. Enzo Biochem had a negative net margin of 24.36% and a negative return on equity of 27.05%. The business had revenue of $31.47 million during the quarter.
In other Enzo Biochem news, major shareholder Discovery Fund Lp Harbert sold 444,768 shares of Enzo Biochem stock in a transaction dated Tuesday, March 16th. The shares were sold at an average price of $4.71, for a total value of $2,094,857.28. 9.40% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its holdings in Enzo Biochem by 40.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 20,988 shares of the medical research company’s stock valued at $43,000 after buying an additional 6,047 shares during the period. Strs Ohio increased its holdings in Enzo Biochem by 3.8% in the 3rd quarter. Strs Ohio now owns 217,000 shares of the medical research company’s stock valued at $457,000 after buying an additional 8,000 shares during the period. Rhumbline Advisers increased its holdings in Enzo Biochem by 13.6% in the 4th quarter. Rhumbline Advisers now owns 77,575 shares of the medical research company’s stock valued at $195,000 after buying an additional 9,309 shares during the period. Virtu Financial LLC bought a new position in Enzo Biochem in the 4th quarter valued at about $31,000. Finally, SG Americas Securities LLC bought a new position in Enzo Biochem in the 4th quarter valued at about $31,000. 60.38% of the stock is currently owned by hedge funds and other institutional investors.
Enzo Biochem Company Profile (NYSE:ENZ)
Enzo Biochem, Inc, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.